Finance

Beta
Lists
MX6A:FRA
Grand Pharmaceutical Group Ltd
€0.54
0.00%
(0.00) 1D
Jun 5, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for MX6A...
Open
€0.54
High
€0.54
Low
€0.54
Mkt. cap
18.42B
Avg. vol.
70.00
Volume
0.00
52-wk high
€1.07
52-wk low
€0.54
No. of employees
13K
Open
€0.54
High
€0.54
Low
€0.54
Mkt. cap
18.42B
Avg. vol.
70.00
Volume
0.00
52-wk high
€1.07
52-wk low
€0.54
No. of employees
13K
News stories
From sources across the web
About Grand Pharmaceutical Group Ltd
CEO-
Employees12.6K
Founded1995
Headquarters-
SectorPharmaceutical industry
Websitegrandpharm.com
Previous reportsAll values in HKD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in HKD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
3.05B
3.05B
3.09B
3.09B
Cost of goods sold
1.25B
1.25B
1.50B
1.50B
Cost of revenue
1.25B
1.25B
1.50B
1.50B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.30B
1.30B
1.29B
1.29B
Operating expense
1.20B
1.20B
1.30B
1.30B
Total operating expenses
2.46B
2.46B
2.80B
2.80B
Operating income
597.85M
597.85M
285.60M
285.60M
Other non operating income
-
-
449.50K
449.50K
EBT including unusual items
673.95M
673.95M
73.09M
73.09M
EBT excluding unusual items
586.65M
586.65M
257.79M
257.79M
Income tax expense
87.01M
87.01M
37.88M
37.88M
Effective tax rate
12.91%
12.91%
51.82%
51.82%
Other operating expenses
-101.79M
-101.79M
-8.97M
-8.97M
Net income
584.51M
584.51M
35.93M
35.93M
Net profit margin
19.14%
19.14%
1.16%
1.16%
Earnings per share
-
-
-
-
Interest and investment income
-
-
3.68M
3.68M
Interest expense
-40.18M
-40.18M
-40.99M
-40.99M
Net interest expenses
-40.18M
-40.18M
-37.31M
-37.31M
Depreciation and amortization charges
-
-
-
-
EBITDA
728.17M
728.17M
426.70M
426.70M
Gain or loss from assets sale
-
-
588.50K
588.50K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer